124 related articles for article (PubMed ID: 36812232)
21. Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.
Karginova O; Siegel MB; Van Swearingen AE; Deal AM; Adamo B; Sambade MJ; Bazyar S; Nikolaishvili-Feinberg N; Bash R; O'Neal S; Sandison K; Parker JS; Santos C; Darr D; Zamboni W; Lee YZ; Miller CR; Anders CK
Mol Cancer Ther; 2015 Apr; 14(4):920-30. PubMed ID: 25824335
[TBL] [Abstract][Full Text] [Related]
22. Association between systemic immune-inflammation index and neoadjuvant chemotherapy efficacy as well as prognosis in triple-negative breast cancer.
Pang J; Wang S; Liao L; Liu X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Sept 28; 46(9):958-965. PubMed ID: 34707005
[TBL] [Abstract][Full Text] [Related]
23. Protein tyrosine phosphatase PTPN13 negatively regulates Her2/ErbB2 malignant signaling.
Zhu JH; Chen R; Yi W; Cantin GT; Fearns C; Yang Y; Yates JR; Lee JD
Oncogene; 2008 Apr; 27(18):2525-31. PubMed ID: 17982484
[TBL] [Abstract][Full Text] [Related]
24. Mutational analysis of FLASH and PTPN13 genes in colorectal carcinomas.
Jeong EG; Lee SH; Yoo NJ; Lee SH
Pathology; 2008 Jan; 40(1):31-4. PubMed ID: 18038312
[TBL] [Abstract][Full Text] [Related]
25. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
Anders CK; Abramson V; Tan T; Dent R
Am Soc Clin Oncol Educ Book; 2016; 35():34-42. PubMed ID: 27249684
[TBL] [Abstract][Full Text] [Related]
26. Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea.
Ryu JM; Choi HJ; Kim I; Nam SJ; Kim SW; Yu J; Lee SK; Choi DH; Park YH; Kim JW; Seo JS; Park JH; Lee JE; Kim SW;
Breast Cancer Res Treat; 2019 Jan; 173(2):385-395. PubMed ID: 30350268
[TBL] [Abstract][Full Text] [Related]
27. Common profiles of Notch signaling differentiate disease-free survival in luminal type A and triple negative breast cancer.
Orzechowska M; Jędroszka D; Bednarek AK
Oncotarget; 2017 Jan; 8(4):6013-6032. PubMed ID: 27888801
[TBL] [Abstract][Full Text] [Related]
28. Effect of caspase-1 (
Peng J; Wei Q; Zhou S; Gu Z; Lv K
Transl Cancer Res; 2023 Aug; 12(8):2138-2154. PubMed ID: 37701103
[TBL] [Abstract][Full Text] [Related]
29. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
Okuma HS; Yonemori K
Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-30e-5p promotes cell growth by targeting PTPN13 and indicates poor survival and recurrence in lung adenocarcinoma.
Zhuang L; Shou T; Li K; Gao CL; Duan LC; Fang LZ; Zhang QY; Chen ZN; Zhang C; Yang ST; Li GF
J Cell Mol Med; 2017 Nov; 21(11):2852-2862. PubMed ID: 28653805
[TBL] [Abstract][Full Text] [Related]
31. Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.
Su Y; Yao Q; Xu Y; Yu C; Zhang J; Wang Q; Li J; Shi D; Yu B; Zeng Y; Zhu X; Bai Q; Zhou X
Front Genet; 2021; 12():674094. PubMed ID: 34917121
[No Abstract] [Full Text] [Related]
32. Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin.
Shen H; Yan W; Yuan J; Wang Z; Wang C
J Exp Clin Cancer Res; 2019 Jun; 38(1):243. PubMed ID: 31174562
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis.
Lin C; Cui J; Peng Z; Qian K; Wu R; Cheng Y; Yin W
Eur J Med Res; 2022 Oct; 27(1):201. PubMed ID: 36242046
[TBL] [Abstract][Full Text] [Related]
34. Mining the prognostic significance and immune infiltration of
Zhou Y; Jiang S; Yu S; Zhu L; Liu Y; Li S; Hao N; Ren Y
Gland Surg; 2022 Apr; 11(4):720-741. PubMed ID: 35531108
[TBL] [Abstract][Full Text] [Related]
35. Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.
Spugnesi L; Gabriele M; Scarpitta R; Tancredi M; Maresca L; Gambino G; Collavoli A; Aretini P; Bertolini I; Salvadori B; Landucci E; Fontana A; Rossetti E; Roncella M; Naccarato GA; Caligo MA
Genes Chromosomes Cancer; 2016 Dec; 55(12):915-924. PubMed ID: 27328445
[TBL] [Abstract][Full Text] [Related]
36. High expression of eIF4E is associated with tumor macrophage infiltration and leads to poor prognosis in breast cancer.
Li F; Sun H; Li Y; Bai X; Dong X; Zhao N; Meng J; Sun B; Zhang D
BMC Cancer; 2021 Dec; 21(1):1305. PubMed ID: 34876062
[TBL] [Abstract][Full Text] [Related]
37. Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway.
Hoover AC; Strand GL; Nowicki PN; Anderson ME; Vermeer PD; Klingelhutz AJ; Bossler AD; Pottala JV; Hendriks WJ; Lee JH
Oncogene; 2009 Nov; 28(45):3960-70. PubMed ID: 19734941
[TBL] [Abstract][Full Text] [Related]
38. Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer.
Yadav S; Ladkany R; Yadav D; Alhalabi O; Khaddam S; Isaac D; Cardenas PY; Zakalik D
Clin Breast Cancer; 2018 Oct; 18(5):e1229-e1235. PubMed ID: 29402697
[TBL] [Abstract][Full Text] [Related]
39. PTEN-PDZ domain interactions: binding of PTEN to PDZ domains of PTPN13.
Sotelo NS; Schepens JT; Valiente M; Hendriks WJ; Pulido R
Methods; 2015 May; 77-78():147-56. PubMed ID: 25448478
[TBL] [Abstract][Full Text] [Related]
40. Machine learning assisted analysis of breast cancer gene expression profiles reveals novel potential prognostic biomarkers for triple-negative breast cancer.
Thalor A; Kumar Joon H; Singh G; Roy S; Gupta D
Comput Struct Biotechnol J; 2022; 20():1618-1631. PubMed ID: 35465161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
